- Manifestation peculiarities of the neurological symptoms of acute polyneuropathies and their differential diagnostics in children during the period of coronavirus disease (COVID-19)
Manifestation peculiarities of the neurological symptoms of acute polyneuropathies and their differential diagnostics in children during the period of coronavirus disease (COVID-19)
Modern Pediatrics. Ukraine. (2023). 3(131): 6-12. doi 10.15574/SP.2023.131.6
Svystilnyk V. O.1, Savinova K. B.2, Krylova V. Y.1, Grychyna L. M.3
1Bogomolets National Medical University, Kyiv, Ukraine
2Shupyk National Healthcare University of Ukraine, Kyiv
3Kyiv City Children Clinical Hospital No. 2, Ukraine
For citation: Svystilnyk VO, Savinova KB, Krylova VY, Grychyna LM. (2023). Manifestation peculiarities of the neurological symptoms of acute polyneuropathies and their differential diagnostics in children during the period of coronavirus disease (COVID-19). Modern Pediatrics. Ukraine. 3(131): 6-12. doi 10.15574/SP.2023.131.6.
Article received: Oct 27, 2022. Accepted for publication: Apr 11, 2023.
The relevance of the problem of diagnosis and treatment of polyneuropathy in children is due to the diverse clinical manifestations of this pathology, which are often acute and can lead to severe, life-threatening complications. Guillain-Barré syndrome (GBS) refers to acute or subacute, often post-infectious, immune-mediated polyneuropathies accompanied by axonal damage to nerve trunks and peripheral nerves. The present study is devoted to the assessment of neurological symptoms in the acute course of GBS, including its differential diagnosis with musculoskeletal lesions in coronavirus disease (COVID-19) in childhood.
Purpose – to determine the features of the debut and characterize the neurological symptoms of acute polyneuropathies in children, including GBS in COVID-19.
Materials and methods. We examined 10 children with confirmed GBS. Clinical-anamnestic, general clinical, clinical-neurological, clinical-instrumental and clinical-laboratory methods of examination were used.
Results. In 1 of the examined patients aged 6 years, GBS developed in the acute period of COVID-19 and manifested as acute flaccid paresis in the distal, and after 4 days – severe weakness of the thigh muscles in combination with leg pain. In 8 of the examined patients, the debut of GBS occurred within 7-21 days after an acute respiratory viral infection. Of these, 6 children had the acute phase of COVID-19 14-21 days before the onset of GBS, which was confirmed by the results of an oropharyngeal PCR-test. The acute phase of COVID-19 in these patients was manifested by fever up to 38.0º, ague, hyposmia, lasting from 3 to 5 days. Severe pain in the legs was noted in all patients with GBS. The absence of elevated levels of creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase according to biochemical blood tests in patients and the absence of myoglobin in the urine excluded rhabdomyolysis of skeletal muscles. Electroneuromyography (ENMG) confirmed the neural type of lesion in the legs.
Conclusions. In most patients, the debut of GBS occurred 3 weeks after the acute phase of COVID-19. Pain syndrome and symmetrical flaccid paresis were the leading symptoms of the course of GBS in children. Reduced excitation conduction velocity along the motor fibres of the tibial and peroneal nerves, according to the results of ENMG, allowed confirming the diagnosis of GBS. Differential diagnosis of GBS with musculoskeletal lesions, in particular, the exclusion of the diagnosis of rhabdomyolysis in COVID-19 in children, allowed for timely prescription of adequate therapy.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of participating institutions. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: SARS-CoV-2, COVID-19, coronavirus disease, acute polyneuropathy, Guillain-Barré syndrome.
REFERENCES
1. Borges Do Nascimento IJ, Cacic N, Abdulazeem HM et al. (2020). Novel Coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med. 9: 941. https://doi.org/10.3390/jcm9040941; PMid:32235486 PMCid:PMC7230636
2. Evtushenko S, Evtushenko O, Suhonosova O. (2016). Neurologiya rannego detskogo vosrasta. Neurology of early children's age. Kiev: Zaslavsky OYu: 288.
3. Evtushenko S, Shajmurzin M, Evtushenko O, Evtushenko I. (2014). Neuromyshechnye zabolevaniya u detey. Neuromuscular Diseases in Children. Donetsk: Knowledge: 218.
4. Fartushna OYe, Palahuta HV, Yevtushenko SK. (2021). Neurological and neuropsychiatric manifestations and complications of SARS-CoV-2 infection: a narrative review and a case presentation in a previously healthy young white adult. International Neurological Journal. 17 (1): 36-41. https://doi.org/10.22141/2224-0713.17.1.2021.226914
5. Korinthenberg R, Trollmann R, Felderhoff-Muser U et al. (2020). Diagnosis and treatment of Guillain-Barre Syndrome in childhood and adolescence: An evidence – and consensus-based guideline. European Journal of Paediatric Neurology. 25: 5-16. https://doi.org/10.1016/j.ejpn.2020.01.003; PMid:31941581
6. Korinthenberg R, Trollmann R, Plecko B et al. (2021). Differential diagnosis of Acquired and Hereditary Neuropathies in Children and Adolescents – Consensus Based Practice Guidelines. Children (Basel). 8 (8): 687. https://doi.org/10.3390/children8080687; PMid:34438578 PMCid:PMC8392610
7. Min Jin, Qiaoxia Tong. (2020). Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 26 (7): 1618-1620. https://doi.org/10.3201/eid2607.200445; PMid:32197060 PMCid:PMC7323559
8. Newton Ch RJC, Procopis P, Prichard JS. (2014). Central Nervous System Infections in Childhood. Oxford: Mac Keith Press: 378.
9. Okhotnikova OM, Ivanova TP, Oshlyanskaya OA et al. (2020). Treatment protocol of coronavirus infection (COVID-19) in children with chronic somatic diseases. Modern pediatrics. 4 (108): 18-32. https://doi.org/10.15574/SP.2020.108.18
10. Ramdas S, Prasad M, Spillane K, Kirkpatrick M. (2013). Acute motor neuropathy with pure distal involvement. A case report of multifocal motor neuropathy. European Journal of Paediatric Neurology. 17: 415-418. https://doi.org/10.1016/j.ejpn.2012.12.005; PMid:23416060
11. Sejvar J, Kohl K, Gidudu J et al. (2011). Guillain-Barre syndrome and Fisher syndrome case definitions and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 29 (3): 599e612. https://doi.org/10.1016/j.vaccine.2010.06.003; PMid:20600491
12. Shaddad AM, Hussein AA, Tohamy AM et al. (2023). Short-term evaluation of motor and sensory nerve conduction parameters on COVID-19 – associated peripheral neuropathy patients. Egypt J Brronchol. 17: 15. https://doi.org/10.1186/s43168-023-00189-3; PMCid:PMC10000350
13. Svystilnyk V, Shkolnyi S. (2022). Differential diagnostics critical illness myopathy and their medical management in children. Modern pediatrics. Ukraine. 2 (122): 72-78. https://doi.org/10.15574/SP.2022.122.72
14. Tsoma EI. (2021). Guillain-Barre syndrome associated with SARS-CoV-2 infection. Clinical case presentation. Ukrainian Neurological Journal. 1-2: 38-42. https://doi.org/10.30978/UNJ2021-1-2-38
15. Van den Bergh PY et al. (2010). European Federation of Neurological Societies, Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Societies guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. European Journal Neurology. Second revision European Journal Neurology, 2021. https://doi.org/10.1111/j.1468-1331.2009.02930.x; PMid:20456730
16. World Health Organization. (2020). Novel-coronavirus 2019. URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed March 11, 2020.